Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Individualisation and personalisation of colorectal cancer treatments

EMCCC 2010

Published: 20 Apr 2010

Views: 11105

Rating:

Save

Prof Eric van Cutsem - University of Leuven, Belgium

Professor van Cutsem discusses the importance of molecular markers in clinical practice, what factors are important in deciding the best treatment for colon cancer and how best to individualise and personalise cancer treatment.

The first Europacolon patients meeting in Lisbon is discussed. This will be the first time bowel cancer patients have had the opportunity to gather and talk about a number of aspects key to this cancer.

Watch Prof van Cutsem present data from the ToGA trial at the ASCO 2009 press conference.
Prof van Cutsem presents updates on the CRYSTAL study at the ESMO 33 press conference.
Prof van Cutsem speaks to ecancertv at ASCO 2009 about research into the treatment of colorectal cancer.

Related Videos

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer